Healthcare entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Active Pharmaceutical Ingredients (APIs), the most common co-covered peer. The 8 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Aug 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Active Pharmaceutical Ingredients (APIs), the most common co-covered peer. The 8 average consequence score is above the beat benchmark of 5.9 in the same window. They are corroborated in line with the beat average, carrying 3 original sources each against 3 for the same window. John Moolenaar appears in 1 tracked Healthcare story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering John Moolenaar. Shared-story counts are live from our verified record — not editorial picks.
A high-profile House Select Committee hearing has highlighted the United States' critical dependence on Chinese active pharmaceutical ingredients (APIs). Lawmakers warn that Beijing is applying its successful industrial playbook from rare earths and EVs to corner the global medicine market, with Chinese pharma revenue projected to hit $2.1 trillion by 2030.
John Moolenaar is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
